Tag Archives: Margaret Hamburg
Ethics in Drug Innovation: The First Hurdle is Trust
By Ansis Helmanis
Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry. This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the podium with Nobel Laureate Professor Elie Wiesel [...]
Posted in Europe, Events, FDA, Global, Guest Blog, Market Access, Patient Communication, Regulatory, healthcare, leadership, pricing Also tagged CMS, Elie Wiesel, EMA, FDA, Guido Rasi, Prix Galien, reimbursement, sequestration Leave a comment
Drug Shortages Still in Focus
By Patricia Van Arnum.
Drug shortages, particularly those for sterile injectable drugs, took center stage last year. In response, industry and the federal government, including FDA, took steps to address the problem. Progress has been made, and Congress is further evaluating if additional steps need to be taken.
Hamburg Delivers DIA Keynote
FDA Commissioner Margaret Hamburg delivered this year’s keynote speech in front of a packed room of pharma and bioscience personnel at the 46th annual meeting of the Drug Information Association, which opened Monday morning. Hamburg started her speech by explaining how her earliest goal as FDA chief was to build the field of regulatory [...]
New FDA Campaign Targets Detailing, Trade Shows
In addition to sending out more warning letters and stepping up enforcement activity, the Food and Drug Administration wants health professionals to do more to police drug marketing and advertising. The agency’s “Bad Ad” program urges doctors and other health professionals to report any false or misleading ads or inappropriate marketing pitches. Depending on one’s [...]
Posted in FDA, News, Regulatory Also tagged Advertising, DDMAC, Detailing, FDA, Marketing, Professional Marketing Leave a comment

Will Congress Provide Sequester "Flexibility" for User Fees?